Merck & Co., Inc. chief financial officer Robert Davis will succeed Kenneth Frazier as CEO effective on 30 June, ushering in a new era for the pharmaceutical giant as it builds out a growth strategy to augment the cancer powerhouse Keytruda (pembrolizumab). As the CEO of Merck & Co. for a decade, Frazier shaped the company from a primary care specialist to an unexpected oncology leader at the forefront of the immuno-oncology frontier.
Davis To Shepherd Merck & Co. Toward The Post-Keytruda Era, As Frazier Exits
Merck & Co.'s CFO Robert Davis will succeed Ken Frazier as CEO. Frazier was one of the architects of the Schering-Plough acquisition, which shaped the pharma for the next decade and delivered its top-selling drug, Keytruda.
More from Leadership
More from Scrip
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.